Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor
This phase III clinical trial is studying how well combination chemotherapy and surgery work in treating young patients with Bilateral Wilms tumor and children who are a special risk for forming tumors in both kidneys. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain after surgery.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- biological : dactinomycin
- drug : cyclophosphamide
- drug : doxorubicin hydrochloride
- drug : carboplatin
- drug : etoposide phosphate
- drug : vincristine sulfate
- procedure : adjuvant therapy
- procedure : neoadjuvant therapy
- procedure : therapeutic conventional surgery
- radiation : Radiation Therapy
Phase: Phase 3
Ages Eligible For Study: